Akcea Therapeutics (NASDAQ:AKCA) had its price objective hoisted by Stifel Nicolaus from $20.00 to $30.00 in a research note released on Friday, March 16th. The firm currently has a buy rating on the stock.
A number of other equities analysts have also recently weighed in on the company. BMO Capital Markets increased their price target on Akcea Therapeutics from $25.00 to $30.00 and gave the stock an outperform rating in a report on Tuesday, February 27th. Wells Fargo cut Akcea Therapeutics from an outperform rating to a market perform rating and set a $27.00 price target for the company. in a report on Tuesday, February 27th. BidaskClub upgraded Akcea Therapeutics from a sell rating to a hold rating in a report on Saturday, January 20th. Zacks Investment Research upgraded Akcea Therapeutics from a hold rating to a buy rating and set a $19.00 target price for the company in a report on Tuesday, January 2nd. Finally, Cowen cut Akcea Therapeutics from an outperform rating to a market perform rating in a report on Tuesday, February 27th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $24.75.
Shares of NASDAQ AKCA traded down $3.11 during mid-day trading on Friday, reaching $21.62. 264,642 shares of the company’s stock were exchanged, compared to its average volume of 468,321. The stock has a market cap of $1,649.99 and a PE ratio of -9.65. Akcea Therapeutics has a 52-week low of $8.10 and a 52-week high of $33.99.
Institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc purchased a new position in Akcea Therapeutics during the 3rd quarter valued at about $111,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Akcea Therapeutics during the 3rd quarter valued at about $180,000. SG Americas Securities LLC purchased a new position in Akcea Therapeutics during the 4th quarter valued at about $121,000. Nationwide Fund Advisors purchased a new position in Akcea Therapeutics during the 3rd quarter valued at about $209,000. Finally, Wells Fargo & Company MN purchased a new position in Akcea Therapeutics during the 3rd quarter valued at about $222,000. Institutional investors own 29.14% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/akcea-therapeutics-akca-earns-buy-rating-from-stifel-nicolaus.html.
Akcea Therapeutics Company Profile
Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.